Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.

Japanese journal of clinical oncology - 1 Feb 2011

Yamashita Keishi, Nagashima Fumio, Fujita Ken-ichi, Yamamoto Wataru, Endo Hisashi, Miya Toshimichi, Narabayashi Masaru, Kawara Kaori, Akiyama Yuko, Ando Yuichi, Ando Masahiko, Sasaki Yasutsuna

Abstract excerpt

OBJECTIVE: This phase I/II study determined the recommended dose of FOLFIRI (irinotecan, infusional 5-fluorouracil and leucovorin) for Japanese patients with advanced colorectal cancer, and evaluated safety at the recommended dose in patients without the UDP-glucuronosyltransferase 1A1*28 allele...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Glucuronosyltransferase

Share to Infusions, Intravenous

Share to Irinotecan

Share to Leucovorin

Share to Maximum Tolerated Dose

Source

Identifiers

PMID: 20965940
DOI: 10.1093/jjco/hyq197

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-20965940-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.PMID 20965940Read ↗

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.Semantic proximity Read ↗

Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.Semantic proximity Read ↗

[Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].Semantic proximity Read ↗

Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.Semantic proximity Read ↗

A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?Semantic proximity Read ↗

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.Semantic proximity Read ↗

Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.Semantic proximity Read ↗

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1 genotyping in previous treated metastatic colorectal cancer patients: study protocol for a randomized controlled trialSemantic proximity Read ↗

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.Semantic proximity Read ↗

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Semantic proximity Read ↗

UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.Semantic proximity Read ↗

Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.